Search Results

Zymo Research, a leader in biotechnological advancement has launched a new nuclease called PureRec Duplex-Specific Nuclease that selectively digests double stranded DNA.

In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A, a challenge that persisted for over half a century.

Zymo Research Corporation proudly announced its sponsorship of the upcoming “Microbes in Wastewater: Molecular Approaches in Pathogen and AMR Surveillance” symposium, scheduled for January 18th -19th, 2024, in Laguna Beach, California.

Zymo Research announced today that the U.S. Food and Drug Administration (FDA) has cleared its DNA/RNA Shield™ SafeCollect™ Saliva Collection Kit as a Class II medical device for microbial nucleic acid storage and stabilization.

Zymo Research, a leading innovation company for biomedical products and services has donated $25,000 to the Regents of the University of California to support the Center for Virus Research at the University of California, Irvine.

Zymo Research, a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex.

Zymo Research, a leading provider in the biomedical industry, has teamed up with Burst Diagnostics, a pioneer in the rapid diagnostics industry, to launch a first-in-class diagnostic platform.

Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -